TLSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TLSIW
TriSalus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.53−0.10 (-2.75%)
Close on Oct 19, 2026
- Market cap
- $205.79M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.49 (−29.68%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TriSalus Life Sciences, Inc. grew revenue 25.2% to $45.08M over the twelve months to Jun 30, 2026. Free cash flow was -$23.28M.
Revenue
$45.08M
+25.2% vs. a year earlier
Operating income
-$30.51M
TTM Q2 2026
Free cash flow
-$23.28M
TTM Q2 2026
EPS, diluted
-$1.30
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $205.79M
- P/E ratio
- –
- Price to sales
- 4.57
- Price to book
- 31.42
- Dividend yield
- –
- Free cash flow yield
- -11.31%
Fundamentals
- Revenue
- $45.08M
- Net income
- -$28.21M
- EPS, diluted
- -$1.30
- Free cash flow
- -$23.28M
- Book value per share
- $0.11
- Diluted shares
- 58M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$45.08M+25.2% YoY
Gross profit
$38.67M+26.9% YoY
Operating income
-$30.51M
Net income
-$28.21M
EPS, diluted
-$1.30
Free cash flow
-$23.28M
Reported periodTrailing twelve months